What is PRP Technology ?
What is RegenPRP™ ?
RegenPRP™: the platelet concentrate prepared with Regen Lab technology provides an autologous reservoir of growth factors.
Platelets, in addition to their role in hemostasis, are key factors in tissue repair mechanisms.1 They provide essential growth factors, such as FGF, PDGF, TGF-β, EGF, VEGF, IGF, which are involved in stem cells migration, differentiation and proliferation. Platelet growth factors also stimulate fibroblasts and endothelial cells to induce the deposition of new extracellular matrix and neovascularisation, respectively.
Plasma contains many factors essential for cell survival including nutrients, vitamins, hormones, electrolytes, growth factors (such as IGF and HGF), and proteins. Among the plasma proteins, the molecules vital for the coagulation process and for formation of the fibrin polymer will serve as a scaffold for cell migration and new tissue generation.2
Platelet-Rich Plasma
• Proven role in the healing of tissues, with key roles in cell migration, proliferation and differentiation
• Mechanism of action comprises anti-inflammatory activity and activation of cell-signalling cascades
• Key role in the synthesis of new extracellular matrix for tissue regeneration
What is ATS ?
ATS is an autologous serum used to activate RegenPRP™ coagulation via a physiological pathway.
This serum contains the enzymes of the coagulation cascade in their active form, among them thrombin. Thrombin is the enzyme that converts soluble plasma fibrinogen to fibrin monomers which polymerise to form the clot. Addition of ATS, either alone or with a calcium solution, to RegenPRP™ triggers the coagulation process in a physiological manner.
This natural process induces the formation of a three-dimensional fibrin matrix in which the platelets are entrapped. This allows a long-lasting growth factor delivery at the treatment site and the fibrin matrix serves as a scaffold for new tissue reconstruction.
PRP gel preparation
The addition of autologous thrombin serum (ATS) to the Regen PRP physiologically starts the coagulation process and thus enables the production of a leukocyte-reduced platelet gel.
Autologous Thrombin Serum (ATS) converts soluble fibrinogen into fibrin monomers, which polymerize into a clot.
This natural process induces the formation of a three-dimensional fibrin matrix in which the platelets are embedded. This enables long-lasting growth factor delivery at the treatment site and the matrix serves as a scaffold for new tissue reconstruction.
The coagulation process is a complex cascade of reactions that causes the thrombin to convert soluble fibrinogen into insoluble fibrin molecules that form the fibrin clot. If calcium is added, this accelerates the process and the fibrin structure is strengthened.
Technological benefits
- Standardized preparation
- Minimum Blood Requirements
- Closed-Loop System: maximized safety
- Stable Physical Separation
- Reversible, Pharmaceutical-Grade Anticoagulation
- pH Neutral Anticoagulant for Patient Tolerability
- Rapid Centrifugation: 5 minutes
- Ease of Preparation: efficient & reproducible
- Facilitates and streamlines routine practice
Biological benefits
- Standardized, Leukocyte-Poor, and Consistent
- Platelet Recovery >80%
- High Platelet Quality: viability & functionality
- Full Plasma Recovery: maximized Growth factor and fibrinogen content
- Maximized Purity: >99.7% RBC depletion
- Extreme Cellular Selectivity: ~96.5% GRN & 70-80% MNC elimination
Scientific benefits
- Demonstrated safety and efficacy
- Evidence-based outcomes for numerous therapeutic indications
- Large number of clinical studies, with over 200 publications
Explore Our Patented Innovations
RegenLab® USA is proud to lead in regenerative medicine with innovative technology designed for efficiency, safety, and flexibility. Our Autologous Thrombin Serum (ATS) is a groundbreaking solution that activates RegenPRP™ coagulation through a physiological pathway. The ATS contains active enzymes from the coagulation cascade, including thrombin, which transforms plasma fibrinogen into fibrin monomers, forming a three-dimensional fibrin matrix.
This natural process ensures the entrapment of platelets within the matrix, enabling sustained growth factor delivery at the treatment site. The fibrin matrix acts as a scaffold for tissue reconstruction, promoting long-lasting regenerative effects.
RegenLab® holds an extensive portfolio of U.S., European, and Swiss patents, including those protecting our advanced ATS technology. Each product undergoes rigorous safety and biocompatibility testing, ensuring compliance with international standards, including CE certification. Our ATS exemplifies our commitment to cutting-edge, patient-centric solutions in regenerative medicine.